Evade EGFR Inhibitor Skin Toxicity Reactions

We’re Seeking Adults 18 or older for a new study that’s evaluating a topical gel to see if it can improve skin toxicities for people prescribed EGFR Inhibitor

medication to help treat their cancer. 


To qualify, please select a study site near your location and complete the intake form via the link above.

About the Study

 We are seeking 152 adult patients 18 years or older at screening  who have been prescribed an approved Epidermal Growth Factor Receptor Inhibitor treatment. Epidermal Growth Factor Receptor Inhibitors (EGFRI), the first targeted cancer therapy, are currently an essential treatment for many cancers including breast cancer, lung cancer, thyroid cancer, colorectal cancer, pancreatic cancer, etc. You may be eligible to participate if you meet these criteria*: 

  • Have not started EGFR Inhibitor therapies yet 
  • Predicted life expectancy ≥ 3 months.
  • Patient is able and willing to comply with contraceptive requirements.
  • Patient must have the ability and willingness to attend the necessary visits (telehealth and in person).

*Other eligibility criteria will apply

To qualify, please select a study site near your location and complete the intake form via the link above.

Who Can Participate?

What is the Study Drug?

What Should I Expect?

If you are interested in learning more about if the CLEER-001 study may be a good fit for you, please submit the intake form. The answers you submit will be used for study purposes only.

Once you submit the form, a member from our team will reach out to you with CLEER-001 resources and connect you with a member of the research team if you may qualify for this study.

Please note that answering these questions does not obligate you to participate in the study. If you have any questions, simply email CLEER001@mbsciences.com

or call (415) 326-8831.

This study will look at the pharmacokinetics (PK) of HT-001 gel**; PK is a measurement of how it enters the bloodstream after it is applied, how long it stays in the bloodstream, how it is metabolized (absorbed in the body), as well as how long it takes to be cleared from your body.

This study will also look at how safe, effective, and tolerable (whether side effects can be handled by subjects) HT-001 gel is compared to placebo in the treatment of skin toxicities associated with EGFRIs***, as well as the impact of HT-001 on subjects’ quality of life.

Before being able to join the CLEER-001 study, individuals will be screened to find out if they are eligible. If they are eligible and choose to take part in this study, they will:

  • Meet with an assigned participating study doctor at the site closest to your location. You will receive either the study topical gel (HT-001) or a placebo (a placebo has no active ingredients).
  • Have up to 10 visits over an 8-week period with dedicated and experienced clinical study staff over who will evaluate your health and progress. If individuals sign up for more information, they can get the run down on logistics of when starting cancer therapy and then waiting for the rash to appear.
  • Take several clinical and safety assessments throughout the 10 visits of the study

All study-related care, including the study required medical tests and investigational study drug, will be provided at no cost to participants. You will receive a stipend for each completed visit.

To qualify, please select a study site near your location and complete the intake form via the link above.

**HT-001 (gel) is a topical (applied to the skin) medication that contains the active ingredient called aprepitant. ***EGFRI - EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR